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With 600,000 cases per year, head and neck cancer was estimated to be the sixth most the remaining results being either invalid (n=2) or negative (n=2). Finally, the vast majority 167 (n=16; 88.9%) of 18 biopsy samples negative by IL were also negative by AP28; only 2 IL-168 negative biopsies were found invalid by AP28. The overall agreement between both assays 169 was good (Cohen's κ coefficient = 0.78). Among the 27 samples that were HPV16-positive 170 with IL, AP28 detected HPV16 in 23 (85.2%), 2 (7.4%) were negative and 2 (7.4%) invalid 171 (Table 1) . AP28 did not detect any HPV16 in samples that were negative for HPV16 with IL. DNA. Indeed, it is well reported that DNA recovering in FFPE specimens may be influenced 210 by several factors, such as formalin quality and concentration, length of fixation, paraffin 211 quality and temperature (30). As a consequence, DNA in FFPE biopsy is either completely or 212 partially degraded into DNA fragments of 200 bp or less (16) . The IL assay relies on the 213 amplification of shorter fragments than AP28 assay, a feature which could partly explain the 214 discrepancies observed between both assays in our series. Furthermore, discordant results 215 could also be associated with extract quantity used for experiment. Thus, the IL assay requires 216 more quantity of tissue extract (10 µl) than AP28 (5 µl), according to manufacturers' 217 instructions. The possibility may be also envisioned that mutations affecting the priming sites 218 of AP28 primers could have led to misdetection. This hypothesis should be however ruled out 219 because the correlation between the efficiency of detection by AP28 and HPV16 viral load 220 was marked. Finally, we checked that observed discrepancies were not due to extraction 221 procedures. 222
In our series, one negative sample by AP28 which was positive by IL was finally 223 diagnosed as positive for HPV16 after analysis of the raw data. This finding indicates that raw 224 data of every AP28 negative samples need to be analyzed in order to detect some of the false-225 negative results. Indeed, the automatic analysis and cut-off used by AP28 test may miss out 226 some HPV-positive samples since the assay was primarily designed to detect HPV on either 227 cervical swab or liquid based cytology specimen and not on FFPE samples from 228 oropharyngeal origin. In practice, the automatic Seegene software interpretation should be 229 used with caution for negative or invalid FFPE biopsies. 230
Our observations indicate that IL as well as AP28 assays could be used in clinical 231 laboratory to detect and genotype HPV in FFPE OPSCC biopsy samples. To our knowledge, 232 only one study compared the performance of the AP28 assay and the CLART system from 233 Genomica (Madrid, Spain) on only 3 FFPE HNSCC samples (27). In our series, the IL assay 234 appeared as sensitive as in-house HPV16 qPCR, in keeping with previous reports showing 235 that IL is highly reliable on FFPE archival samples. Nevertheless, the AP28 technic could be 236 preferred depending on the recruitment of the laboratory, particularly if the number of 237 samples is important. Indeed, AP28 relies on real-time PCR, which allows easier and faster 238 procedure as compared with IL technic which appears more cumbersome and requires 239 specific material for hybridization on membrane following PCR amplification. In addition, the 240 risk of cross contamination between samples is less important with AP28 than with IL. 241
However, it should be kept in mind that misdetection of HPV16-positive biopsies could occur 242 with AP28 assay. Since HPV16 is known to be the most prevalent HPV genotype in OPSCC, 243 diagnosed in 85% of cases (26), one could strongly recommend confirming the negative 244 results by AP28 with HPV16 genotype-specific molecular assay validated on FFPE samples. 245
In our laboratory, we have chosen to screen first for HPV16 by in-house HPV16 qPCR, and 246 then to test further the negative samples with IL or AP28 to potentially detect less common 247 genotypes in OPSCC, or confirm the negativity for HPV. 248
In conclusion, our observations demonstrate that both commercially available IL and 249 
